相关实验视频

Updated: Jun 28, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

革命性治疗:对于BCG不响应的非肌肉侵入性膀癌的突破性方法

Maciej Jaromin¹, Tomasz Konecki¹, Piotr Kutwin¹

¹1st Department of Urology, Medical University of Lodz, 93-513 Lodz, Poland.

|April 13, 2024

概括

新的保守治疗方法为对Bacillus Calmette-Guérin (BCG) 无反应的非肌肉侵入性膀癌 (NMIBC) 提供了希望. 这些进展旨在通过延迟激进囊切除来保持生活质量.

科学领域:

在瘤学瘤学.
泌尿器科泌尿器科泌尿器科泌尿器科

背景情况:

在全球范围内,非肌肉侵入性膀癌 (NMIBC) 约占所有膀癌诊断的80%.
对于NMIBC的标准治疗包括膀瘤的顺尿切除 (TURBT) 和静脉内巴西卡尔梅特-盖林 (BCG) 灌注.
对BCG不响应的NMIBC存在有限的治疗选择,往往需要进行激进囊切除术.

研究的目的:

审查BCG不响应的NMIBC保守治疗策略的最新进展.
突出FDA批准的药物,并探索新兴的治疗可能性.

主要方法:

对NMIBC新型治疗方法的当前文献和临床数据的审查.
专注于FDA批准的药物,如Pembrolizumab和Nadofaragene Firadenovec (Adstiladrin) 等药物. 这些药物是美国食品和药物管理局批准的药物.
包括其他有前途的疗法,如N-803免疫疗法,TAR-200,TAR-210和组合化疗方案.

主要成果:

布罗利祖马布和纳多法拉基尼费拉登诺维克 (Adstiladrin) 是FDA批准的BCG不响应的NMIBC的选择.
新兴的治疗方法,如N-803免疫疗法和静脉内输送系统 (TAR-200,TAR-210) 显示出潜力.
组合化疗方案也在进行研究.

结论:

对BCG不响应的NMIBC的保守管理提供了一个有希望的未来.
通过这些新的治疗方法推迟激进囊切除可以显著改善患者的生活质量.
这些进展代表了管理BCG不响应的NMIBC的未来方向.

关键词:

艾德斯蒂拉德林 (Adstiladrin) 是一种可供使用的药物.在BCG灌注中使用BCG灌注.没有对BCG反应的BCG不响应.N-803 这是一本书.在 NMIBC 中,NMIBC 是一个非常重要的机构.这就是Pembrolizumab.在TAR-200中,它是TAR-200.化疗化疗是一种化学疗法.进行保守的治疗.免疫疗法免疫疗法

更多相关视频

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...